IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial DeploymentAccesswire · Oct 13, 2026
IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%Defense World · Oct 3, 2026
IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026Accesswire · Sep 28, 2026
IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment ClosureAccesswire · Aug 17, 2026
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline ReadoutAccesswire · Aug 11, 2026
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short CampaignAccesswire · Jul 29, 2026IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.02 | -$0.03 | Miss |
| May 15, 2026 | -$0.02 | -$0.02 | Beat |
| Mar 20, 2026 | -$0.02 | -$0.02 | Beat |
| Nov 14, 2025 | -$0.02 | -$0.02 | Beat |
| Aug 19, 2025 | -$0.03 | -$0.02 | Beat |
| Jun 30, 2025 | -$0.02 | -$0.02 | Beat |